BRPI0821168B8 - isolated antibody that binds to human IL-21, or a fragment thereof, uses of said antibody or fragment, and, hybridoma - Google Patents

isolated antibody that binds to human IL-21, or a fragment thereof, uses of said antibody or fragment, and, hybridoma

Info

Publication number
BRPI0821168B8
BRPI0821168B8 BRPI0821168A BRPI0821168A BRPI0821168B8 BR PI0821168 B8 BRPI0821168 B8 BR PI0821168B8 BR PI0821168 A BRPI0821168 A BR PI0821168A BR PI0821168 A BRPI0821168 A BR PI0821168A BR PI0821168 B8 BRPI0821168 B8 BR PI0821168B8
Authority
BR
Brazil
Prior art keywords
human
fragment
antibody
binds
cells
Prior art date
Application number
BRPI0821168A
Other languages
Portuguese (pt)
Inventor
M Krejsa Cecile
C Yi Eugene
J Ramsdell Frederick
W Rixon Mark
R Dillon Stacey
R Jaspers Stephen
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of BRPI0821168A2 publication Critical patent/BRPI0821168A2/en
Publication of BRPI0821168B1 publication Critical patent/BRPI0821168B1/en
Publication of BRPI0821168B8 publication Critical patent/BRPI0821168B8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Abstract

anticorpo isolado que se liga ao il-21 humano, ou uma porção deste que se liga ao antígeno, usos de dito anticorpo, e, hibridoma. anticorpos monoclonais il-21 anti-humanos humanos e os hibridomas que os produzem são apresentados. alguns destes anticorpos têm a capacidade de ligar um il-21 humano natural, uma proteína il-21 recombinante humana e/ou regiões de peptídeo de il-21 humano. estes anticorpos anti-il-21 humanos são úteis no tratamento terapêutico de doencças antoimunes e inflamatórias, particularmente doenças mediadas por células auxiliares foliculares t, células b, células th ou células th 17.isolated antibody that binds to human IL-21, or a portion thereof that binds to the antigen, uses of said antibody, and, hybridoma. human anti-human monoclonal antibodies IL-21 and the hybridomas that produce them are shown. some of these antibodies have the ability to bind a natural human IL-21, a recombinant human IL-21 protein and/or peptide regions of human IL-21. these anti-human IL-21 antibodies are useful in the therapeutic treatment of anti-immune and inflammatory diseases, particularly diseases mediated by follicular helper cells, b cells, th cells or th cells 17.

BRPI0821168A 2007-12-07 2008-12-08 isolated antibody that binds to human IL-21, or a fragment thereof, uses of said antibody or fragment, and, hybridoma BRPI0821168B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1232907P 2007-12-07 2007-12-07
US61/012329 2007-12-07
PCT/IB2008/005011 WO2010055366A2 (en) 2007-12-07 2008-12-08 Anti-human il-21 monoclonal antibodies

Publications (3)

Publication Number Publication Date
BRPI0821168A2 BRPI0821168A2 (en) 2015-10-27
BRPI0821168B1 BRPI0821168B1 (en) 2021-01-12
BRPI0821168B8 true BRPI0821168B8 (en) 2021-05-25

Family

ID=40899470

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821168A BRPI0821168B8 (en) 2007-12-07 2008-12-08 isolated antibody that binds to human IL-21, or a fragment thereof, uses of said antibody or fragment, and, hybridoma

Country Status (18)

Country Link
US (5) US7883700B2 (en)
EP (3) EP3103813A1 (en)
JP (3) JP5745274B2 (en)
KR (2) KR101591316B1 (en)
CN (2) CN102027011B (en)
AU (1) AU2008364115B2 (en)
BR (1) BRPI0821168B8 (en)
CA (2) CA2707026C (en)
DK (1) DK2217268T3 (en)
ES (2) ES2584237T3 (en)
HU (1) HUE027828T2 (en)
IL (2) IL205976A (en)
MX (1) MX2010006181A (en)
PL (1) PL2217268T3 (en)
PT (1) PT2217268T (en)
RU (1) RU2504552C2 (en)
WO (1) WO2010055366A2 (en)
ZA (1) ZA201004046B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1963369B1 (en) 2005-11-28 2013-05-15 Zymogenetics, Inc. Il-21 antagonists
CA2707026C (en) 2007-12-07 2017-04-11 Zymogenetics, Inc. Anti-human il-21 monoclonal antibodies
EP2596023A4 (en) * 2010-07-20 2014-03-05 Beth Israel Hospital Compositions and methods featuring il-6 and il-21 antagonists
JP2014506259A (en) * 2011-01-17 2014-03-13 ノヴォ ノルディスク アー／エス IL-21 ligand
CN103702721A (en) * 2011-05-31 2014-04-02 诺沃—诺迪斯克有限公司 IL-21 epitope and IL-21 ligands
SG11201401202YA (en) * 2011-10-19 2014-06-27 Morphosys Ag Antagonists of il17c for the treatment of inflammatory disorders
EP2746292A1 (en) 2012-12-21 2014-06-25 Novo Nordisk A/S Anti-IL21 antibodies for use in the treatment of nephropathies
EP2746293A1 (en) 2012-12-21 2014-06-25 Novo Nordisk A/S Anti-IL21 antibodies for use in the treatment of cardiovascular diseases
JP6563389B2 (en) * 2013-06-27 2019-08-21 モナッシュ ユニバーシティ IL-21 binding protein and use thereof
CN103487572B (en) * 2013-10-08 2017-03-29 北京大学人民医院 Application of the folliculus helper T cell (Tfh) in autoimmune disease state of an illness early warning
CN104721820A (en) * 2013-12-24 2015-06-24 信达生物制药(苏州)有限公司 Application of bispecific monoclonal antibody to treatment of uveitis
WO2015132241A1 (en) * 2014-03-03 2015-09-11 Novo Nordisk A/S Treatment of inflammatory diseases
AR099625A1 (en) * 2014-03-21 2016-08-03 Lilly Co Eli IL-21 ANTIBODIES
CA3208721A1 (en) * 2014-04-08 2015-10-15 Boston Pharmaceuticals Inc. Binding molecules specific for il-21 and uses thereof
US10105442B2 (en) 2014-05-07 2018-10-23 Novo Nordisk A/S Treatment of diabetes type 1 using GLP-1 and anti-IL-21
RU2609627C2 (en) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" High affinity and aggregationally stable antibodies based on vl variable domains and vhh derivative
US10662240B2 (en) 2014-12-19 2020-05-26 Mabtech Ab Composition, kit and method for inhibition of IL-21 mediated activation of human cells
WO2016094962A1 (en) 2014-12-19 2016-06-23 Monash University Il-21 antibodies
CN109069600B (en) * 2016-03-31 2023-03-28 伊莱利利公司 IL-21 antibodies and uses thereof
WO2018045273A2 (en) * 2016-09-02 2018-03-08 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
JP6952295B2 (en) * 2016-09-09 2021-10-20 国立大学法人金沢大学 Method for producing human anti-HLA monoclonal antibody
SI3661954T1 (en) 2017-08-03 2022-05-31 Amgen Inc. Interleukin-21 muteins and methods of treatment
BR112020014121A2 (en) 2018-01-12 2020-12-01 Amgen Inc. anti-pd-1 antibodies and treatment methods
CN115666704A (en) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 Ingestible device for delivery of therapeutic agents to the gastrointestinal tract
EP4178605A1 (en) * 2020-07-13 2023-05-17 Transgene Treatment of immune depression

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE3668186D1 (en) 1985-04-01 1990-02-15 Celltech Ltd TRANSFORMED MYELOMA CELL LINE AND METHOD USING THE SAME FOR EXPRESSING A GENE ENCODING AN EUKARYONTIC POLYPEPTIDE.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3883899T3 (en) 1987-03-18 1999-04-22 Sb2 Inc CHANGED ANTIBODIES.
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
ATE377076T1 (en) 1999-03-09 2007-11-15 Zymogenetics Inc HUMAN CYTOKINE AS A LIGAND OF THE ZALPHA RECEPTOR AND ITS USES
AU2001253127A1 (en) 2000-04-05 2001-10-23 Zymogenetics Inc. Soluble zalpha11 cytokine receptors
CA2413258C (en) 2000-06-30 2012-01-03 Zymogenetics, Inc. Interferon-like protein zcyto21
ATE448301T1 (en) 2000-09-08 2009-11-15 Univ Zuerich COLLECTION OF PROTEINS WITH REPEATING SEQUENCES (REPEAT PROTEINS) THAT CONTAIN REPETITIVE SEQUENCE MODULES
EP2357187A1 (en) 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
CA2448123C (en) 2001-05-24 2012-09-11 Zymogenetics, Inc. Taci-immunoglobulin fusion proteins
DK1451322T3 (en) 2001-11-05 2010-02-01 Zymogenetics Inc IL-21 antagonists
US20040028665A1 (en) 2002-01-08 2004-02-12 Garner Bryan E. Compositions and methods for inhibiting pathogenic growth
AU2003230834A1 (en) 2002-04-09 2003-10-27 Beth Israel Deaconess Medical Center, Inc. Antagonists of il-21 and modulation of il-21-mediated t cell responses
US20040016010A1 (en) 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
EP2377547A1 (en) 2002-06-07 2011-10-19 ZymoGenetics, Inc. Use of IL-21 as an antimicrobial agent
CN1688340A (en) 2002-07-15 2005-10-26 韦思公司 Methods and compositions for modulating T helper (TH) cell development and function
CA2501616C (en) 2002-10-08 2015-05-12 Immunomedics, Inc. Antibody therapy
US20070092485A1 (en) 2002-11-15 2007-04-26 Zymogenetics, Inc. Cytokine zalpha11 ligand
KR101098897B1 (en) 2002-12-13 2011-12-26 지모제넥틱스, 인코포레이티드 -21 -21 production in prokaryotic hosts
WO2004056392A1 (en) 2002-12-23 2004-07-08 Innate Pharma Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same
WO2004083249A2 (en) * 2003-03-14 2004-09-30 Wyeth Antibodies against human il-21 receptor and uses therefor
CA2518854A1 (en) * 2003-03-21 2004-10-07 Wyeth Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor
WO2005037306A1 (en) 2003-10-17 2005-04-28 Novo Nordisk A/S Combination therapy
JP4471721B2 (en) 2004-04-20 2010-06-02 独立行政法人産業技術総合研究所 Anti-interleukin 21 receptor (IL-21R) antibody and hybridoma producing this antibody
AU2005244942A1 (en) 2004-05-19 2005-12-01 Wyeth Modulation of immunoglobulin production and atopic disorders
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
WO2006135385A2 (en) 2004-08-05 2006-12-21 Wyeth Antagonizing interleukin-21 receptor activity
KR100654124B1 (en) 2004-11-18 2006-12-08 주식회사 하이닉스반도체 Method for fabrication of semiconductor device capable of protecting bunker defect
ITRM20040586A1 (en) * 2004-11-29 2005-02-28 Giuliani Spa ANTIGENIC EPITOPES OF INTERLEUCHINA-21, RELATIVE ANTIBODIES AND THEIR USE IN MEDICAL FIELD.
WO2006105538A2 (en) * 2005-03-31 2006-10-05 Centocor, Inc. Methods and compositions for treating il-21 related pathologies
DK200501310A (en) * 2005-09-21 2005-10-01 Novo Nordisk As The invention relates to the treatment or prevention of autoimmune diseases and latent autoimmune diabetes in the adults
EP1963369B1 (en) 2005-11-28 2013-05-15 Zymogenetics, Inc. Il-21 antagonists
JP2009517406A (en) 2005-11-28 2009-04-30 ザイモジェネティクス， インコーポレイテッド IL-21 receptor antagonist
CA2707026C (en) 2007-12-07 2017-04-11 Zymogenetics, Inc. Anti-human il-21 monoclonal antibodies

Also Published As

Publication number Publication date
US8124089B2 (en) 2012-02-28
IL205976A (en) 2015-08-31
US20110130548A1 (en) 2011-06-02
EP2217268A2 (en) 2010-08-18
WO2010055366A3 (en) 2010-10-21
RU2504552C2 (en) 2014-01-20
BRPI0821168A2 (en) 2015-10-27
JP6027668B2 (en) 2016-11-16
KR101615215B1 (en) 2016-04-25
CN102027011B (en) 2014-09-03
RU2010123049A (en) 2012-01-20
CN102027011A (en) 2011-04-20
WO2010055366A4 (en) 2012-08-16
US20100041873A1 (en) 2010-02-18
JP5745274B2 (en) 2015-07-08
EP3103813A1 (en) 2016-12-14
US20090191214A1 (en) 2009-07-30
JP2011506422A (en) 2011-03-03
CN103772502B (en) 2017-03-29
KR20160022386A (en) 2016-02-29
US20120225065A1 (en) 2012-09-06
KR101591316B1 (en) 2016-02-05
JP2016033150A (en) 2016-03-10
AU2008364115A1 (en) 2010-05-20
EP2426146A3 (en) 2012-05-30
CA2707026A1 (en) 2010-05-20
US7883700B2 (en) 2011-02-08
KR20100097724A (en) 2010-09-03
EP2426146B1 (en) 2016-02-17
IL239947A0 (en) 2015-08-31
DK2217268T3 (en) 2016-08-15
EP2426146A2 (en) 2012-03-07
CA2910933A1 (en) 2010-05-20
PT2217268T (en) 2016-07-28
CA2910933C (en) 2017-04-11
EP2217268B1 (en) 2016-05-04
HUE027828T2 (en) 2016-11-28
US8241629B2 (en) 2012-08-14
IL205976A0 (en) 2010-11-30
AU2008364115B2 (en) 2013-11-21
JP5848384B2 (en) 2016-01-27
MX2010006181A (en) 2010-07-01
PL2217268T3 (en) 2016-12-30
US8226948B1 (en) 2012-07-24
ZA201004046B (en) 2011-04-28
US8361470B2 (en) 2013-01-29
CN103772502A (en) 2014-05-07
ES2572231T3 (en) 2016-05-30
BRPI0821168B1 (en) 2021-01-12
WO2010055366A2 (en) 2010-05-20
JP2014129387A (en) 2014-07-10
CA2707026C (en) 2017-04-11
US20120177655A1 (en) 2012-07-12
IL239947A (en) 2016-03-31
ES2584237T3 (en) 2016-09-26

Similar Documents

Publication Publication Date Title
BRPI0821168B8 (en) isolated antibody that binds to human IL-21, or a fragment thereof, uses of said antibody or fragment, and, hybridoma
HRP20201191T1 (en) Multispecific mutated antibody fab fragments
EA201190132A1 (en) HUMANIZED ANTIBODIES, CONNECTING CD19, AND THEIR APPLICATION
ES2494190T3 (en) Anti-adrenomedulin antibody (ADM) or anti-ADM antibody fragment or protein scaffold without anti-ADM Ig to reduce the risk of mortality in a patient suffering from a chronic or acute disease or an acute condition
CO6231038A2 (en) UNION PROTEINS, INCLUDING ANTIBODIES DERIVED FROM ANTIBODY AND ANTIBODY FRAGMENTS THAT SPECIFICALLY JOIN CD154 AND ITS USES
RU2012129735A (en) ANTIBODIES TO HER3 AND THEIR APPLICATIONS
JP7257971B6 (en) Anti-CD40 Antibodies, Antigen-Binding Fragments Thereof, and Medical Uses Thereof
PE20110225A1 (en) COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING COMPLEMENT PROTEIN C5
MA32725B1 (en) Antibodies to 17li and associated uses
PE20140882A1 (en) NEUTRALIZING ANTIBODIES OF HUMAN CYTOMEGALOVIRUS
PE20080181A1 (en) ANTIBODIES THAT BIND TO BETA-AMYLOID PEPTIDE IN THE TREATMENT OF ALZHEIMER
CY1115456T1 (en) METHOD OF ADJUSTMENT OF ANTI-ANTI-IL-5
RS52889B (en) Therapeutic human anti-il-1r1 monoclonal antibody
NZ596409A (en) Anti macrophage migration inhibitory factor antibodies
AR067199A1 (en) PROTEINS OF UNION TO ANTIGENS THAT JOIN PAR-2
PE20110668A1 (en) ANTI-STROMAL THYMIC LYMPHOPOYETIN ANTIBODIES (ANTI-TSLP)
PE20081625A1 (en) IL-17 A RECEPTOR ANTIGEN BINDING PROTEINS
AR062895A1 (en) COMPOSITIONS AND METHODS RELATED TO GLUCAGON RECEIVING ANTIBODIES
PE20140633A1 (en) NEUTRALIZING ANTIBODIES ANTI-CCL20
AR058955A1 (en) IMMUNGLOBULINS THAT JOIN INTERLEUQUINA 13
AR072985A1 (en) TREATMENT FOR AN AUTOIMMUNE DISEASE OR INFLAMMATORY DISORDER, PROCEDURE, ANTIBODY, UNION PROTEIN
UA109633C2 (en) HUMAN ANTIBODY AGAINST TISSUE FACTOR
NO20092121L (en) Humanized anti-factor D antibodies and uses thereof
BRPI0607486A2 (en) humanized l243 antibody, bispecific antibody or antigen binding fragments thereof, pharmaceutical composition, kit and use of said antibodies
RS53793B1 (en) Humanized antibodies to amyloid beta

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.1 NA RPI NO 2589 DE 18/08/2020 POR TER SIDO INDEVIDA.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF